M Laura Gómez Jaramillo has a degree in Biology from the University of Seville (2006) and a Master's degree in Biomedical Research from the same university (2007). Her Doctorate from the University of Cadiz (Extraordinary Doctorate Award in the 2014/2015 academic year) was in the field of intracellular membrane traffic and vesicle secretion from plasma cells. Collaborations were established with the HHUU Puerta del Mar Immunology Unit, thus actively participating in several projects related to Multiple Myeloma, Rheumatoid Arthritis and Lupus Erythematosus. She has directed a doctoral thesis in 2019 entitled "Transcriptional regulation of the PRDM1 gene in human plasma cells and its possible involvement in myeloma" with a grade of Outstanding Cum Laude. All her publications are in prestigious journals both in the field of Immunology and in Endocrinology and Diabetes indexed in Q1. Dr Gómez currently directs the preclinical research line corresponding to the study of the complications of T1DM in the kidney, within the group of 'Diabetes and its associated complications' at INIBICA. Since she joined the group in 2018, Dr Gómez has obtained funding for a project as Principal Investigator (Plan Propio INIBICA- LI19/09-IN-C17). She participates as a collaborator in the clinical trials network (RIC-0539-2018, IP: Francisco Tinahones Madueño) and other FIS, Consejería and ITI projects (IPs; Ana I. Arroba Espinosa and Manuel Aguilar Diosdado).
M Laura Gómez Jaramillo has a degree in Biology from the University of Seville (2006) and a Master's degree in Biomedical Research from the same university (2007). Her Doctorate from the University of Cadiz (Extraordinary Doctorate Award in the 2014/2015 academic year) was in the field of intracellular membrane traffic and vesicle secretion from plasma cells. Collaborations were established with the HHUU Puerta del Mar Immunology Unit, thus actively participating in several projects related to Multiple Myeloma, Rheumatoid Arthritis and Lupus Erythematosus. She has directed a doctoral thesis in 2019 entitled "Transcriptional regulation of the PRDM1 gene in human plasma cells and its possible involvement in myeloma" with a grade of Outstanding Cum Laude. All her publications are in prestigious journals both in the field of Immunology and in Endocrinology and Diabetes indexed in Q1. Dr Gómez currently directs the preclinical research line corresponding to the study of the complications of T1DM in the kidney, within the group of 'Diabetes and its associated complications' at INIBICA. Since she joined the group in 2018, Dr Gómez has obtained funding for a project as Principal Investigator (Plan Propio INIBICA- LI19/09-IN-C17). She participates as a collaborator in the clinical trials network (RIC-0539-2018, IP: Francisco Tinahones Madueño) and other FIS, Consejería and ITI projects (IPs; Ana I. Arroba Espinosa and Manuel Aguilar Diosdado).